[go: up one dir, main page]

FR3115682B1 - Compositions à base de méthyl-cyclodextrines pour le traitement et/ou la prévention de la stéatose hépatique - Google Patents

Compositions à base de méthyl-cyclodextrines pour le traitement et/ou la prévention de la stéatose hépatique Download PDF

Info

Publication number
FR3115682B1
FR3115682B1 FR2011361A FR2011361A FR3115682B1 FR 3115682 B1 FR3115682 B1 FR 3115682B1 FR 2011361 A FR2011361 A FR 2011361A FR 2011361 A FR2011361 A FR 2011361A FR 3115682 B1 FR3115682 B1 FR 3115682B1
Authority
FR
France
Prior art keywords
methyl
prevention
treatment
cyclodextrins
hepatic steatosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR2011361A
Other languages
English (en)
Other versions
FR3115682A1 (fr
Inventor
Daniel Wils
Caroline Perreau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roquette Freres SA
Original Assignee
Roquette Freres SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR2011361A priority Critical patent/FR3115682B1/fr
Application filed by Roquette Freres SA filed Critical Roquette Freres SA
Priority to AU2021374726A priority patent/AU2021374726A1/en
Priority to US18/251,358 priority patent/US20240000827A1/en
Priority to PCT/EP2021/025430 priority patent/WO2022096151A1/fr
Priority to CA3197127A priority patent/CA3197127A1/fr
Priority to MX2023005255A priority patent/MX2023005255A/es
Priority to JP2023525452A priority patent/JP2023547633A/ja
Priority to EP21805838.6A priority patent/EP4240371A1/fr
Priority to CN202180074737.6A priority patent/CN116456991A/zh
Priority to KR1020237018567A priority patent/KR20230093516A/ko
Publication of FR3115682A1 publication Critical patent/FR3115682A1/fr
Application granted granted Critical
Publication of FR3115682B1 publication Critical patent/FR3115682B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention est relative à une nouvelle utilisation d’une composition pharmaceutique comprenant au moins une méthyl-cyclodextrine dans le traitement et/ou la prévention de la stéatose hépatique et maladies associées. Elle concerne également l’utilisation de méthyl-cyclodextrine pour réduire la stockage de lipides dans le foie.
FR2011361A 2020-11-05 2020-11-05 Compositions à base de méthyl-cyclodextrines pour le traitement et/ou la prévention de la stéatose hépatique Active FR3115682B1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
FR2011361A FR3115682B1 (fr) 2020-11-05 2020-11-05 Compositions à base de méthyl-cyclodextrines pour le traitement et/ou la prévention de la stéatose hépatique
CN202180074737.6A CN116456991A (zh) 2020-11-05 2021-11-04 包含甲基环糊精的用于治疗和/或预防肝脂肪变性的组合物
PCT/EP2021/025430 WO2022096151A1 (fr) 2020-11-05 2021-11-04 Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de la steatose hepatique
CA3197127A CA3197127A1 (fr) 2020-11-05 2021-11-04 Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de la steatose hepatique
MX2023005255A MX2023005255A (es) 2020-11-05 2021-11-04 Composiciones que comprenden metilciclodextrinas para el tratamiento y/o la prevencion de la esteatosis hepatica.
JP2023525452A JP2023547633A (ja) 2020-11-05 2021-11-04 脂肪肝の治療及び／又は予防のためのメチルシクロデキストリンを含む組成物
AU2021374726A AU2021374726A1 (en) 2020-11-05 2021-11-04 Compositions comprising methyl cyclodextrins for the treatment and/or prevention of hepatic steatosis
US18/251,358 US20240000827A1 (en) 2020-11-05 2021-11-04 Compositions comprising methyl cyclodextrins for the treatment and/or prevention of hepatic steatosis
KR1020237018567A KR20230093516A (ko) 2020-11-05 2021-11-04 간 지방증의 치료 및/또는 예방을 위한 메틸 사이클로덱스트린을 포함하는 조성물
EP21805838.6A EP4240371A1 (fr) 2020-11-05 2021-11-04 Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de la steatose hepatique

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2011361A FR3115682B1 (fr) 2020-11-05 2020-11-05 Compositions à base de méthyl-cyclodextrines pour le traitement et/ou la prévention de la stéatose hépatique
FR2011361 2020-11-05

Publications (2)

Publication Number Publication Date
FR3115682A1 FR3115682A1 (fr) 2022-05-06
FR3115682B1 true FR3115682B1 (fr) 2023-02-24

Family

ID=75278079

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2011361A Active FR3115682B1 (fr) 2020-11-05 2020-11-05 Compositions à base de méthyl-cyclodextrines pour le traitement et/ou la prévention de la stéatose hépatique

Country Status (10)

Country Link
US (1) US20240000827A1 (fr)
EP (1) EP4240371A1 (fr)
JP (1) JP2023547633A (fr)
KR (1) KR20230093516A (fr)
CN (1) CN116456991A (fr)
AU (1) AU2021374726A1 (fr)
CA (1) CA3197127A1 (fr)
FR (1) FR3115682B1 (fr)
MX (1) MX2023005255A (fr)
WO (1) WO2022096151A1 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60032388T2 (de) 1999-11-12 2008-01-10 Frères Roquette Kristalline mischungen aus teilmethylethern des beta-cyclodextrins und verwandten verbindungen
FR3014694B1 (fr) * 2013-12-13 2016-11-11 Roquette Freres Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de maladies par augmentation du taux de cholesterol-hdl
MY193765A (en) * 2015-02-16 2022-10-27 Univ Queensland Sulfonylureas and related compounds and use of same
RO133396A0 (ro) * 2018-12-05 2019-06-28 Universitatea De Vest "Vasile Goldiş" Din Arad Sistem drug delivery crisină - random methyl - beta cyclodextrin () cu potenţial antifibrotic ridicat în prevenţia/regenerarea leziunilor fibrotice hepatice

Also Published As

Publication number Publication date
EP4240371A1 (fr) 2023-09-13
FR3115682A1 (fr) 2022-05-06
AU2021374726A1 (en) 2023-06-08
AU2021374726A9 (en) 2024-09-26
US20240000827A1 (en) 2024-01-04
CN116456991A (zh) 2023-07-18
MX2023005255A (es) 2023-07-24
WO2022096151A1 (fr) 2022-05-12
JP2023547633A (ja) 2023-11-13
KR20230093516A (ko) 2023-06-27
CA3197127A1 (fr) 2022-05-12

Similar Documents

Publication Publication Date Title
MA40814A1 (fr) Compositions pharmaceutiques pour thérapie combinée
MA52154B1 (fr) Composition pharmaceutique pour l'anémie
MA53076B1 (fr) Compositions solides comportant un agoniste glp-1, du sel d'acide n-(8-(2-hydroxybenzoyl)amino)caprylate et un lubrifiant
Chan et al. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis
Fraunfelder Corneal toxicity from topical ocular and systemic medications
MA52492B1 (fr) Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés
MA26728A1 (fr) COMPOSITION PHARMACEUTIQUE COMPRENANT UN INHIBITEUR DE CYP2D6 ET UN MÉDICAMENT à MÉTABOLISME CATALYSÉ PAR CYP2D6
Thapa et al. Evaluation and comparison of bond strength to 10% carbamide peroxide bleached enamel following the application of 10% and 25% sodium ascorbate and alpha-tocopherol solutions: An: in vitro: study
FR3063645B1 (fr) Acefapc pour le traitement des maladies acetylcholine dependantes
Younis et al. High-density lipoprotein impedes glycation of low-density lipoprotein
TNSN07426A1 (fr) Composition pharmaceutique comprenant un antiviral,un antitumoral ou un antiparasitaire, et un actif choisi parmi le carveol, le thymol, l'eugenol le borneol et le carvacrol
FR3115682B1 (fr) Compositions à base de méthyl-cyclodextrines pour le traitement et/ou la prévention de la stéatose hépatique
MA31130B1 (fr) Combinaison comprenant un chelatant du fer et un agent antineoplasique et ses applications
AU2009300331A1 (en) Stabilized composition for treating psoriasis
Ames et al. Thrombocytopaenia in antiphospholipid syndrome: a free radical perspective
Ashok et al. Necrotizing scleritis associated with rheumatoid arthritis: long-term remission with high-dose infliximab therapy
MA49959B1 (fr) Formulation liposomale pour lubrification d'articulation
Rose et al. Dose-dependent induction of IL-6 by plant-derived proteases in vitro
MA56608B1 (fr) Composition et utilisation d'une solution ophtalmique à base d'acide hyaluronique et d'arabinogalactane
Felekos et al. PCSK9 inhibitors for the management of dyslipidemia in people with type 2 diabetes: how low is too low?
MA62939A1 (fr) Composition pharmaceutique de pembrolizumab et son utilisation
Kruh et al. Evaluation of the effect of N-acetylcysteine on protein deposition on contact lenses in patients with the Boston Keratoprosthesis type I
FR3096579B1 (fr) composition pour la protection et la reparation de la barriere hematoencephalique (BHE)
FR3123563B1 (fr) Utilisation de l’amitriptyline et/ou l’un de ses sels pharmaceutiquement acceptable comme agent conservateur
MA58507A1 (fr) Composition pharmaceutique aqueuse de levilimab

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20220506

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5